Related Experiment Video
Updated: Jun 29, 2025
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
Tumour size predicts risk of recurrence in tall cell subtype papillary thyroid carcinoma
David Leong1, Connull Leslie2, Brodie Laurie3
1Endocrine Surgical Services Unit, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, Australia; School of Surgery, The University of Western Australia, Nedlands, Australia.
Background:
The tall cell subtype of papillary thyroid cancer (TCPTC) is the most common aggressive subtype and often treated aggressively. This approach may not be necessary in smaller tumours without adverse histological characteristics.
Methods:
97 patients with TCPTC defined as a height-to-width ratio of ≥3:1 and at least 30% tall cells were compared against 390 classical papillary thyroid carcinoma (CPTC) based on tumour size with recurrence free survival (RFS) as the primary outcome.
Results:
TCPTC are more likely to present with adverse histological characteristics. In smaller tumours (<2 cm), only central lymph node metastasis (HR7.16 p = 0.03) and multifocality (HR10.11 p = 0.026) increased recurrence risk. In larger tumours, TCPTC histology (HR3.78 p = 0.002), lymphovascular invasion (HR3.02 p = 0.014) and central lymph node metastasis (HR3.24 p < 0.001) significantly increased recurrence risk.
Conclusion:
TCPTC tumours <2 cm without central lymph node metastasis and multifocality are similar in risk of recurrence to classical PTC and could be managed with lobectomy.
